167 results
Page 6 of 9
8-K
EX-99.1
lcj8hl5s4 331153
3 Jun 20
Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
7:26am
8-K
EX-99.2
9hslxmtp3xe7lh2m
3 Jun 20
Regulation FD Disclosure
7:25am
8-K
EX-10.1
u2skke56oj2vo rl
9 Dec 19
Departure of Directors or Certain Officers
5:02pm
8-K
EX-4.1
jlmq2eh0 325ia6t
18 Nov 19
Replimune Announces Proposed Public Offering
8:02am
8-K
EX-1.1
3m218xowt d6l3g6cc
18 Nov 19
Replimune Announces Proposed Public Offering
8:02am
424B5
7rks6ypf4xkhjaw i50v
18 Nov 19
Prospectus supplement for primary offering
7:40am
424B5
85kha96yd05 f3
12 Nov 19
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
3vpiy77q gw4j
15 Oct 19
Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma
8:24am
UPLOAD
wwp9j180uw
12 Aug 19
Letter from SEC
12:00am
DEF 14A
wfj8n3ko 7b03grzznx7
9 Aug 19
Definitive proxy
4:05pm
8-K
EX-10.2
hzmf5fq
8 Aug 19
Entry into a Material Definitive Agreement
5:14pm
S-3
EX-4.4
2ojca0 yn
8 Aug 19
Shelf registration
5:05pm
S-3
07cmvst7vwx7w2
8 Aug 19
Shelf registration
5:05pm